Phase I/II clinical trials of the subunit coronavirus vaccine Betuvax-CoV-2 have begun in Russia. IN
"Betuvax-CoV-2" - a vaccine against the new coronavirustype, developed by the company of the same name, Betuvax, and the Human Stem Cell Institute. This is the first subunit recombinant vaccine in Russia. It contains an artificially synthesized surface protein of SARS-CoV-2. As a rule, such vaccines have the fewest side effects. In addition, they are much easier to adapt to new strains of the virus.
Preclinical studies have already been conducted in Russiavaccine "Betuvax-CoV-2". It turned out to be safe for animals. Also, after administration of the drug, the experimental subjects observed active production of high titers of neutralizing antibodies against the new type of coronavirus.
Human stem cell institute - Russianbiotechnology holding, founded in 2003. Leads the development and provides services related to cellular, gene and post-genomic technologies.
Read more
Astronomers accidentally find two galaxies at the edge of space and time
People first descended to the bottom of the "Hell's Well": what did they find there
Chinese jet drone flies a record 20 hours at a speed of 800 km / h